{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:04:29Z","timestamp":1793754269551,"version":"4.6.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.dsx.2024.103034","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:07:11Z","timestamp":1714867631000},"page":"103034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-6137","authenticated-orcid":false,"given":"Mohammad Shafi","family":"Kuchay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dsx.2024.103034_bib1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jhep.2016.06.010","article-title":"Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood","volume":"65","author":"Valenti","year":"2016","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.dsx.2024.103034_bib2","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.3390\/ijms20112841","article-title":"NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management","volume":"20","author":"Lonardo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib3","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/hep.25559","article-title":"Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease","volume":"55","author":"Guy","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dsx.2024.103034_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, small molecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"issue":"10213","key":"10.1016\/j.dsx.2024.103034_bib5","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.dsx.2024.103034_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrendo.2014.143","article-title":"Thyroid hormone receptors and resistance to thyroid hormone disorders","volume":"10","author":"Ortiga-Carvalho","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.dsx.2024.103034_bib7","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1210\/en.2017-00250","article-title":"Thyroid hormone signaling pathways: time for a more precise nomenclature","volume":"158","author":"Flamant","year":"2017","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.dsx.2024.103034_bib8","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1073\/pnas.97.4.1444","article-title":"The subcellular localization of acetyl-CoA carboxylase 2","volume":"97","author":"Abu-Elheiga","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.dsx.2024.103034_bib9","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00018-009-0035-1","article-title":"Structural insight into function and regulation of carnitine palmitoyltransferase","volume":"66","author":"Rufer","year":"2009","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.dsx.2024.103034_bib10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1194\/jlr.M051664","article-title":"Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans","volume":"55","author":"Bonde","year":"2014","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.dsx.2024.103034_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0006-2952(98)00119-1","article-title":"Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression","volume":"56","author":"Ness","year":"1998","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.dsx.2024.103034_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1006\/abbi.1995.0061","article-title":"Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7 alpha hydroxylase by thyroid hormone","volume":"323","author":"Ness","year":"1995","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/0002-9343(90)90530-Q","article-title":"Biochemical basis of thyroid hormone action in the heart","volume":"88","author":"Dillmann","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.dsx.2024.103034_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11901-024-00639-6","article-title":"Endocrinology for the hepatologist","volume":"23","author":"Isaacs","year":"2024","journal-title":"Curr Hepat Rep"},{"issue":"4","key":"10.1016\/j.dsx.2024.103034_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3350\/cmh.2015.21.4.372","article-title":"Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: a 4-year retrospective cohort study","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"10.1016\/j.dsx.2024.103034_bib29","first-page":"584","article-title":"Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors","volume":"16","author":"Eshraghian","year":"2013","journal-title":"Arch Iran Med"},{"issue":"4","key":"10.1016\/j.dsx.2024.103034_bib30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000454920","article-title":"Nonalcoholic fatty liver disease is not associated with thyroid hormone levels and hypothyroidism: a systematic review and meta-analysis","volume":"6","author":"Jaruvongvanich","year":"2017","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.dsx.2024.103034_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fendo.2017.00335","article-title":"Relationship between hypothyroidism and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.dsx.2024.103034_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dsx.2024.103034_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2024.103034_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10620-011-2006-2","article-title":"Prevalence of hypothyroidism in nonalcoholic fatty liver disease","volume":"57","author":"Pagadala","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.dsx.2024.103034_bib17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jhep.2012.05.025","article-title":"Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study","volume":"57","author":"Xu","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/thy.2011.0279","article-title":"Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania","volume":"22","author":"Ittermann","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.dsx.2024.103034_bib19","article-title":"Hepatic steatosis and thyroid function tests in overweight and obese children","volume":"2013","author":"Pacifico","year":"2013","journal-title":"Internet J Endocrinol"},{"key":"10.1016\/j.dsx.2024.103034_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12902-015-0030-5","article-title":"Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years","volume":"15","author":"Ludwig","year":"2015","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"10.1016\/j.dsx.2024.103034_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12664-015-0541-z","article-title":"Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India","volume":"34","author":"Parikh","year":"2015","journal-title":"Indian J Gastroenterol"},{"issue":"8","key":"10.1016\/j.dsx.2024.103034_bib22","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of nonalcoholic fatty liver disease: the rotterdam study","volume":"101","author":"Bano","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dsx.2024.103034_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ijpo.12110","article-title":"Thyroid dysfunction and hepatic steatosis in overweight children and adolescents","volume":"12","author":"Kaltenbach","year":"2017","journal-title":"Pediatr Obes"},{"issue":"7","key":"10.1016\/j.dsx.2024.103034_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ueg2.12124","article-title":"Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany","volume":"9","author":"Labenz","year":"2021","journal-title":"United European Gastroenterol J"},{"issue":"17","key":"10.1016\/j.dsx.2024.103034_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025738","article-title":"The relationship between non-alcoholic fatty liver disease and hypothyroidism: a systematic review and meta-analysis","volume":"100","author":"Zeng","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.dsx.2024.103034_bib31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/me.2008-0311","article-title":"Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms","volume":"23","author":"Araki","year":"2009","journal-title":"Mol Endocrinol"},{"issue":"12","key":"10.1016\/j.dsx.2024.103034_bib32","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/a-1404-7939","article-title":"Thyroid hormone deficiency modifies hepatic lipid droplet morphology and molecular properties in lithogenic-diet supplemented mice","volume":"129","author":"Kube","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/thy.2021.0621","article-title":"Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary mouse model of nonalcoholic steatohepatitis","volume":"32","author":"Zhou","year":"2022","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib34","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metabol Syndr"},{"issue":"1","key":"10.1016\/j.dsx.2024.103034_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.dsx.2024.103034_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2265.2008.03348.x","article-title":"Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism","volume":"70","author":"Torun","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.dsx.2024.103034_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.intimp.2012.08.010","article-title":"Oxidative stress parameters in serum and low density lipoproteins of Hashimoto's thyroiditis patients with subclinical and overt hypothyroidism","volume":"14","author":"\u00d6zt\u00fcrk","year":"2012","journal-title":"Int Immunopharm"},{"issue":"8","key":"10.1016\/j.dsx.2024.103034_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-2007-981457","article-title":"Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment","volume":"115","author":"Baskol","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"10.1016\/j.dsx.2024.103034_bib39","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1210\/en.2014-1302","article-title":"Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism","volume":"155","author":"Bohinc","year":"2014","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.dsx.2024.103034_bib40","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1530\/EC-18-0499","article-title":"Reduced expression of thyroid hormone receptor \u03b2 in human nonalcoholic steatohepatitis","volume":"7","author":"Krause","year":"2018","journal-title":"Endocr Connect"},{"issue":"9","key":"10.1016\/j.dsx.2024.103034_bib41","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2009-0212","article-title":"Thyroid hormone-related regulation of gene expression in human fatty liver","volume":"94","author":"Pihlajam\u00e4ki","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.dsx.2024.103034_bib42","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1096\/fj.08-108464","article-title":"Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats","volume":"22","author":"Perra","year":"2008","journal-title":"Faseb J"},{"issue":"2","key":"10.1016\/j.dsx.2024.103034_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dsx.2024.103034_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/hep.22783","article-title":"Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease","volume":"49","author":"Arrese","year":"2009","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.dsx.2024.103034_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126329","article-title":"Myelin repair stimulated by CNS-selective thyroid hormone action","volume":"4","author":"Hartley","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.dsx.2024.103034_bib46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1089\/thy.2022.0612","article-title":"Maternal administration of the CNS-selective sobetirome prodrug sob-AM2 exerts thyromimetic effects in murine MCT8-deficient fetuses","volume":"33","author":"Valc\u00e1rcel-Hern\u00e1ndez","year":"2023","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study","volume":"2","author":"Sjouke","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.dsx.2024.103034_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240338","article-title":"Regulation of gene transcription by thyroid hormone receptor \u03b2 agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"15","author":"Luong","year":"2020","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.dsx.2024.103034_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313105","article-title":"TG68, a novel thyroid hormone receptor-\u03b2 agonist for the treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dsx.2024.103034_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1127517","article-title":"Potential use of TG68 - a novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis","volume":"13","author":"Caddeo","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.dsx.2024.103034_bib51","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib52","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.3390\/ijms24065843","article-title":"Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-\u03baB signaling pathways in an RGS5-dependent manner","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.dsx.2024.103034_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213714","article-title":"Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196","volume":"23","author":"H\u00f6nes","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.dsx.2024.103034_bib54","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"A Highly Selective Thyroid Hormone Receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.dsx.2024.103034_bib55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.dsx.2024.103034_bib56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib57","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2024.103034_bib58","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease#:\u223c:text=Today%2C%20the%20U.S.%20Food%20and,along%20with%20diet%20and%20exercise."},{"issue":"6","key":"10.1016\/j.dsx.2024.103034_bib59","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212400095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212400095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T04:28:15Z","timestamp":1726633695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187140212400095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S187140212400095X"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2024.103034","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2024.103034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103034"}}